| Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. | |
| | |
MedLine Citation:
|
PMID: 18765509 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
INTRODUCTION: Asoprisnil, a novel orally active selective progesterone receptor modulator, is being studied for the management of symptomatic uterine leiomyomata. The exact mechanism of action is not yet discerned. The primary objectives of this double-blind, randomized, placebo-controlled study included evaluation of the effect of asoprisnil on uterine artery blood flow. Furthermore, we assessed effects of asoprisnil on leiomyoma symptoms. PATIENTS AND METHODS: Thirty-three premenopausal patients scheduled for hysterectomy due to symptomatic uterine leiomyomata were recruited in four centers and treated with 10 or 25 mg asoprisnil or placebo for 12 wk before surgery. At baseline and before hysterectomy, all patients underwent sonographic assessment to measure impedance to uterine artery blood flow, determined by resistance index and pulsatility index, as well as volumes of largest leiomyoma and uterus. In addition, patients recorded intensity and frequency of menstrual bleeding on a menstrual pictogram. Each asoprisnil treatment was compared with placebo. RESULTS: The increased pulsatility index in both asoprisnil groups and the statistically significantly increased resistance index within the 25-mg asoprisnil group suggest a moderately decreased uterine artery blood flow. Analysis of menstrual pictogram scores showed a statistically significant larger decrease in frequency and intensity of bleeding for both asoprisnil groups compared with placebo. Bleeding was suppressed by asoprisnil 25mg in 91% of patients. Asoprisnil treatment was well tolerated when administered daily for a 12-wk period, and no serious adverse events occurred. CONCLUSION: Asoprisnil moderately reduced uterine artery blood flow. This effect may contribute in part to the clinical effects of asoprisnil. |
| | |
Authors:
|
Julia Wilkens; Kristof Chwalisz; Cong Han; Jane Walker; Iain T Cameron; Susan Ingamells; Alexandra C Lawrence; Mary Ann Lumsden; Dharani Hapangama; Alistair R W Williams; Hilary O D Critchley |
Related Documents
:
|
6478009 - Blood sampling from the ovarian vein in the unstressed pregnant guinea pig. 3993989 - Decidua-associated changes in guinea pig uterine blood flow and volume: relation to ute... 305959 - Modification of oestrogen-induced uterine hyperaemia by drugs in the ovariectomized rat. 9418709 - Vasodilator effects of estrogen are not diminished by androgen in postmenopausal women. 2595989 - Timing the mating of dogs on the basis of blood progesterone concentration. 4039609 - Study of the luteinizing hormone-induced increase of ovarian blood flow during the estr... 19874669 - A fatality from an oral ingestion of methamphetamine. 7424549 - Videodensitometry for measuring blood vessel diameter. 22305939 - Noninvasive in vitro measurement of pig-blood d-glucose by using a microwave cavity sen... |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't Date: 2008-09-02 |
Journal Detail:
|
Title: The Journal of clinical endocrinology and metabolism Volume: 93 ISSN: 0021-972X ISO Abbreviation: J. Clin. Endocrinol. Metab. Publication Date: 2008 Dec |
Date Detail:
|
Created Date: 2008-12-05 Completed Date: 2009-01-27 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0375362 Medline TA: J Clin Endocrinol Metab Country: United States |
Other Details:
|
Languages: eng Pagination: 4664-71 Citation Subset: AIM; IM |
Affiliation:
|
Centre for Reproductive Biology, University of Edinburgh, The Queen's Medical Research Institute, 47 Little France Crescent, Edinburgh EH16 4TJ, United Kingdom. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Arteries / drug effects Data Interpretation, Statistical Double-Blind Method Endometrium / pathology Estrenes / pharmacology* Female Humans Hysterectomy* Leiomyoma / drug therapy*, surgery* Menstruation / drug effects Middle Aged Myometrium / pathology Ovary / drug effects, physiology* Oximes / pharmacology* Pregnanediol / blood Quality of Life Receptors, Progesterone / drug effects* Regional Blood Flow / drug effects Ultrasonography, Doppler, Color Uterine Hemorrhage / complications, prevention & control Uterine Neoplasms / drug therapy*, surgery* Uterus / blood supply* Vascular Resistance / drug effects |
| Chemical | |
Reg. No./Substance:
|
0/Estrenes; 0/Oximes; 0/Receptors, Progesterone; 0/asoprisnil; 26445-07-8/Pregnanediol |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The effects of central adiposity on growth hormone (GH) response to GH-releasing hormone-arginine st...
Next Document: Mechanism for improved insulin sensitivity after gastric bypass surgery.